Table Of Contents
1 Introduction 30
1.1 Objectives Of The Study 30
1.2 Market Definition 30
1.3 Overview Of Europe Wound Care Biologics Market 30
1.4 Currency And Pricing 31
1.5 Limitation 31
1.6 Markets Covered 32
2 Market Segmentation 34
2.1 Markets Covered 34
2.2 Geographic Scope 35
2.3 Years Considered For The Study 36
2.4 Currency And Pricing 36
2.5 Research Methodology 37
2.6 Primary Interviews With Key Opinion Leaders 40
2.1 Dbmr Market Position Grid 41
2.2 Dbmr Market Challenge Matrix 42
2.3 Secondary Sources 43
2.4 Assumptions 43
3 Market Overview 44
3.1 Drivers 46
3.1.1 Increasing Cases Of Diabetic Foot Ulcers 46
3.1.2 Increasing Incidences Of Burn Cases 46
3.1.3 Rising Number Of Geriatric Population 47
3.1.4 Innovation In Wound Care Biologics 48
3.1.5 New Product Launches 50
3.2 Restrains 50
3.2.1 High Cost Of Wound Treatment And Wound Care Biologics 50
3.2.2 Risk Of Skin Substitue Failure 51
3.3 Opportunities 52
3.3.1 3D Skin Printing 52
3.3.2 Awareness Programs 53
3.4 Challenges 54
3.4.1 Lack Of Wound Management Services 54
4 Executive Summary 55
5 Premium Insights 58
6 Europe Wound Care Biologics Market, By Product Type 63
6.1 Overview 64
6.2 Synthetic Skin Grafts 66
6.3 Growth Factors 67
6.3.1 Platelet Derived Growth Factor (Pdgf) 70
6.3.2 Platelet Rich Plasma (Prp) 70
6.3.3 Epidermal Growth Factors (Egf) 70
6.3.4 Basic Fibroblast Growth Factors (Bfgf) 71
6.3.5 Granulocyte Colony Stimulating Factor (G-Csf) 71
6.3.6 Talactoferrin Alfa 71
6.3.7 Thrombin Peptide 72
6.3.8 Keratinocy Growth Factor (Kgf) 72
6.4 Allografts 73
6.5 Xenografts 74
7 Europe Wound Care Biologics Market, By Wound Type 76
7.1 Overview 77
7.2 Wounds 78
7.2.1 Surgical Wound 80
7.2.1.1 Skin Surgery 81
7.2.1.1.1 Wound Closure 82
7.2.1.1.2 Skin Biopsy 82
7.2.1.1.3 Skin Flap 82
7.2.1.1.4 Skin Graft 82
7.2.1.1.5 Others 82
7.2.1.2 Cosmetic Procedure 83
7.2.1.2.1 Brest Enhancement 84
7.2.1.2.2 Facial Contouring 85
7.2.1.2.3 Facial Rejuvenation; 85
7.2.1.2.4 Body Contouring 85
7.2.1.2.5 Skin Rejuvenation 85
7.2.1.2.6 Others 86
7.2.1.3 Gynecologic Procedures 86
7.2.1.3.1 Pubovaginalis Sling 86
7.2.1.3.2 Pelvic Floor Reconstruction 87
7.2.1.3.3 Rectocele Repair Surgery 87
7.2.1.3.4 Others 87
7.2.1.4 Gastrointestinal Procedure 87
7.2.1.4.1 General Gastrointestinal Surgery 88
7.2.1.4.2 Hernia 89
7.2.1.4.3 Others 89
7.2.2 Acute Wounds 90
7.2.3 Chronic Wounds 90
7.2.4 Traumatic Wounds 91
7.3 Burns 91
7.3.1 Ulcers 92
7.3.2 Diabetic Ulcers 94
7.3.3 Pressure Ulcer 94
7.3.4 Venous Ulcer 95
7.3.5 Others 95
8 Europe Wound Care Biologics Market, By End User 96
8.1 Overview 97
8.2 Hospitals 99
8.3 Wound Care Centers 100
8.4 Ambulatory Surgical Centers 101
8.5 Clinics 103
8.6 Community Healthcare Center 104
9 Europe Wound Care Biologics Market; Geography 105
9.1 Europe 105
9.1.1 Germany 117
9.1.2 France 124
9.1.3 U.K. 131
9.1.4 Italy 138
9.1.5 Switzerland 145
9.1.6 Netherlands 152
9.1.7 Russia 160
9.1.8 Turkey 167
9.1.9 Spain 174
9.1.10 Belgium 181
9.1.11 Rest Of Europe 188
10 Europe Wound Care Biologics Market, Company Landscape 189
10.1 Company Share Analysis; Europe 189
11 Company Profile 190
11.1 Mimedx. 190
11.1.1 Company Overview 190
11.1.2 Revenue Analysis; 190
11.1.3 Company Share Analysis; 191
11.1.4 Product Portfolio 191
11.1.5 Recent Developments 192
11.2 Organogenesis Inc 193
11.2.1 Company Overview 193
11.2.2 Geographic Presence 193
11.2.3 Company Share Analysis; 194
11.2.4 Product Portfolio 194
11.2.5 Recent Developments 195
11.3 Integra Lifesciences 196
11.3.1 Company Overview 196
11.3.2 Revenue Analysis 196
11.3.3 Company Share Analysis; 197
11.3.4 Product Portfolio 197
11.3.5 Recent Developments 198
11.4 Convatec Inc. 199
11.4.1 Company Overview 199
11.4.2 Revenue Analysis 199
11.4.3 Company Share Analysis; 200
11.4.4 Product Portfolio ; 200
11.4.5 Recent Developments 200
11.5 Acell Inc. 201
11.5.1 Company Overview 201
11.5.2 Product Portfolio 201
11.5.3 Recent Developments 202
11.6 Allosource 203
11.6.1 Company Overview 203
11.6.2 Product Portfolio 203
11.6.3 Recent Developments 204
11.7 Alphatec Spine, Inc. ( A Subsidary Of Alphatec Holdings, Inc) 205
11.7.1 Company Overview 205
11.7.2 Product Portfolio 205
11.7.3 Recent Developments 205
11.8 Amnio Technology, Llc 206
11.8.1 Company Overview 206
11.8.2 Product Portfolio 206
11.8.3 Recent Developments 207
11.9 Amniox Medical, Inc. 208
11.9.1 Company Overview 208
11.9.2 Product Portfolio 208
11.9.3 Recent Developments 209
11.10 Anika Therapeutics, Inc. 210
11.10.1 Company Overview 210
11.10.2 Revenue Analysis 210
11.10.3 Product Portfolio 211
11.10.4 Recent Developments 211
11.11 Biohorizons Iph, Inc ( A Subsidary Of Henry Schein, Inc.) 212
11.11.1 Company Overview 212
11.11.2 Geographicpresence 212
11.11.3 Product Portfolio 213
11.11.4 Recent Developments 213
11.12 Kerecis 214
11.12.1 Company Overview 214
11.12.2 Geographical Presence 214
11.12.3 Product Portfolio 215
11.12.4 Recent Developments 215
11.13 Marine Polymer Technologies, Inc 216
11.13.1 Company Overview 216
11.13.2 Product Portfolio 216
11.13.3 Recent Developments 216
11.14 M?lnlycke Health Care Ab 217
11.14.1 Company Overview 217
11.14.2 Revenue Analysis 217
11.14.3 Product Portfolio 218
11.14.4 Recent Developments 218
11.15 Osiris Therapeutics, Inc. 219
11.15.1 Company Overview 219
11.15.2 Revenue Analysis 219
11.15.3 Product Portfolio 220
11.15.4 Recent Developments 220
11.16 Skye Biologics Inc. 221
11.16.1 Company Overview 221
11.16.2 Product Portfolio ; 221
11.16.3 Recent Development; 222
11.17 Smith And Nephew 223
11.17.1 Company Overview 223
11.17.2 Revenue Analysis 223
11.17.3 Product Portfolio 224
11.17.4 Recent Developments 224
11.18 Solsys Medical. 225
11.18.1 Company Overview 225
11.18.2 Product Portfolio 226
11.18.3 Recent Developments 226
11.19 Vericel Corporation. 227
11.19.1 Company Overview 227
11.19.2 1.1.2 Revenue Analysis 227
11.19.3 Product Portfolio 228
11.19.4 Recent Developments 228
11.20 Wright Medical Group N.V 229
11.20.1 Company Overview 229
11.20.2 1.1.2 Revenue Analysis 229
11.20.3 Product Portfolio 230
11.20.4 Recent Developments 231
12 Related Reports 232
?